We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisers Recommend Approving Gilead’s Quad HIV Treatment
FDA Advisers Recommend Approving Gilead’s Quad HIV Treatment
May 18, 2012
Gilead Sciences’ Quad HIV treatment has an acceptable benefit-risk profile and should be approved with robust postmarket strings attached, FDA reviewers say.